Abstract
Reasons for failure of the immune system to fight cancer include tumor immune escape mechanisms, limited availability of tumor-specific antigens, and failure to deliver tumor antigens in the right immunological context. Progress in molecular biology and immunology has provided technologies that can detect an ever-widening choice of new tumor-specific antigens. One of the most important questions remains the delivery of these tumor antigens in an effective way to the immune system of a cancer patient. This task is performed in normal circumstances by dendritic cells (DCs). DCs are sentinels of the immune system located at sites of antigen entry such as skin. They take up antigen and carry it to secondary lymphoid organs. They are highly specialized antigen-presenting cells (APCs) for the activation of specific effector T cells recirculating in secondary lymphoid organs. In recent years an enormous increase in our understanding of DC biology has opened up new ways of applying these cells for immunotherapy of cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Abbreviations
- Abbreviations:
-
APC, antigen presenting cell; CR, complete remission, CTL, cytotoxic T-lymphocyte; DC, dendritic cell; DDC, dermal dendritic cell; DTH, delayed-type hypersensitivity; FLT-3, fms-like tyrosine kinase 3; FCS, fetal calf serum; GM-CSF, granulocyte/macrophage-colony stimulating factor; HLA, histocompatibility leukocyte antigen; IFN, interferon; CR, complete response; JL, interleukin; KLH, keyhole limpet hemocyanin; LC, Langerhans cell; MHC, major histocompatibility complex;MoDC, monocyte derived dendritic cells; MR, mixed response; PBS, phosphate-buffered saline; PD, progressive disease; PR, partial response; SD, stable disease.
References
Banchereau J, Briere F, Caux C, et al. (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767–811.
Nestle FO, Bancereau J, Hart D (2001) Dendritic cells: on the move from bench to bedside. Nat Med 7:761–765.
Timmerman JM, Levy R (1999) Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 50:507–529.
Fong L, Engleman EG (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245–273.
Mukherji B, Chakraborty NG, Yamasaki S, et al. (1995) Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 92:8078–8082.
Hu X, Chakraborty NG, Sporn}R, et al. (1996) Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 56:2479–2483.
Markowicz S, Engleman EE (1990) Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in-vitro. J Clin Invest 85:955–961.
Hsu FJ, Benike C, Liles FFTM, et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52–58.
Thurner B, Haendle I, Roder C, et al. (1999) Vaccination with mage-3Al peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669–1678.
Mackensen A, Herbst B, Chen JL, et al. (2000) Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 86:385–392.
Lau R, Wang F, Jeffery G, et al. (2001) Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24:66–78.
Reichardt VL, Okada CY, Liso A, et al. (1999) Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma — a feasibility study. Blood 93:2411–2419.
Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML (2000) Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 60:829–833.
Murphy GP, Tjoa BA, Simmons SJ, et al. (1999) Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38:73–78.
Burch PA, Breen JK, Buckner JC, et al. (2000) Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer (in process citation). Clin Cancer Res 6:2175–2182.
Mackensen A, Drager R, Schlesier M, Mertelsmann R, Lindemann A (2000) Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother 49:152–156.
Lotze MT, Shurin M, et al. (2000) Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity. Cancer J Sci Am 6 [Suppl]:S61–66.
Panelli MC, Wunderlich J, et al. (2000) Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated MART-1 and gplOO. J Immunother 23:487–498.
Morse MA, Deng Y, et al. (1999) A phase I study of active inmmunotherapy with carcinoembryonic antigen peptide (CAP-1=-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 5:1331–1338.
Holtl L, Rieser C, Papesh C, Ramoner R, Bartsch G, Thurnher M (1998) CD83+ blood dendritic cell as a vaccine for immunotherapy of metastasic renal-cell cancer. Lancet 352:1368.
Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate pulsed dendritic cells. Nature Med 4:328–332.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Nestle, F.O. (2002). Dendritic Cell Vaccination for the Treatment of Skin Cancer. In: Dummer, R., Nestle, F.O., Burg, G. (eds) Cancers of the Skin. Recent Results in Cancer Research, vol 160. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59410-6_20
Download citation
DOI: https://doi.org/10.1007/978-3-642-59410-6_20
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63969-2
Online ISBN: 978-3-642-59410-6
eBook Packages: Springer Book Archive